author-photo

Oliver M. Bautista

Merck & Co.

36

Papers

3084

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

2020 EClinicalMedicine
Show All
- Source
- Cite
- Save
Citations (30)
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up

2020 Human Vaccines & Immunotherapeutics
Show All
- Source
- Cite
- Save
Citations (4)
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

2020 Papillomavirus Research
Show All
- Source
- Cite
- Save
Citations (9)
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects

2019 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (21)
Long term immunogenicity and effectiveness of the 9-valent HPV vaccine in preadolescents and adolescents

2019 Pediatrics
Show All
- Source
- Cite
- Save
Citations (1)
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine

2019 Human Vaccines & Immunotherapeutics
Show All
- Source
- Cite
- Save
Citations (2)
Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine

2017 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (4)
KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials

2017 Papillomavirus Research
Show All
- Source
- Cite
- Save
Citations (15)
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)